Z
Zyversa Therapeutics Inc
NASDAQ:ZVSA
Zyversa Therapeutics Inc
NASDAQ:ZVSA
Price:
0.2
USD
4.17%
Market Closed
Market Cap:
$1.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Z
|
Zyversa Therapeutics Inc
NASDAQ:ZVSA
|
US |
|
O
|
Oisix Ra Daichi Inc
TSE:3182
|
JP |
|
Deutsche Wohnen SE
OTC:DTCWY
|
DE |
|
Kuangli Bio Tech Holdings Co Ltd
TWSE:6431
|
TW |
|
A
|
Aileron Therapeutics Inc
NASDAQ:ALRN
|
US |
|
SSI Liquidating Inc
OTC:SCOO
|
US |
|
GlaxoSmithKline PLC
LSE:GSK
|
UK |
|
Inter RAO YEES PAO
MOEX:IRAO
|
RU |
|
Contact Energy Ltd
NZX:CEN
|
NZ |
|
S
|
Solaria Energia y Medio Ambiente SA
MAD:SLR
|
ES |
|
Guangdong Sanhe Pile Co Ltd
SZSE:003037
|
CN |
|
ScanTech AI Systems Inc
NASDAQ:STAI
|
US |
|
B
|
Bekasi Fajar Industrial Estate Tbk PT
IDX:BEST
|
ID |
|
U
|
Ulusal Faktoring AS
IST:ULUFA.E
|
TR |
|
Garbi Finvest Ltd
BSE:539492
|
IN |
|
S
|
SNTEnergy Co Ltd
KRX:100840
|
KR |
Income Statement
Earnings Waterfall
Zyversa Therapeutics Inc
Zyversa Therapeutics Inc
Income Statement
Zyversa Therapeutics Inc
Zyversa Therapeutics Inc
Currency: USD
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
1
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(8)
|
(9)
|
(9)
|
(10)
|
(14)
|
(15)
|
(18)
|
(18)
|
(14)
|
(106)
|
(22)
|
(22)
|
(9)
|
(8)
|
|
| Selling, General & Administrative |
(6)
|
(7)
|
(6)
|
(6)
|
(8)
|
(9)
|
(12)
|
(13)
|
(11)
|
(10)
|
(8)
|
(8)
|
(7)
|
(7)
|
|
| Research & Development |
(2)
|
(3)
|
(3)
|
(5)
|
(6)
|
(6)
|
(6)
|
(5)
|
(3)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
| Depreciation & Amortization |
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(93)
|
(12)
|
(12)
|
0
|
0
|
|
| Operating Income |
(8)
N/A
|
(9)
-15%
|
(9)
0%
|
(10)
-17%
|
(14)
-33%
|
(15)
-9%
|
(18)
-22%
|
(18)
+3%
|
(14)
+19%
|
(106)
-635%
|
(22)
+79%
|
(22)
+3%
|
(9)
+58%
|
(8)
+7%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(81)
|
(81)
|
(93)
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(8)
N/A
|
(10)
-20%
|
(10)
+1%
|
(11)
-19%
|
(15)
-30%
|
(16)
-6%
|
(100)
-537%
|
(99)
+1%
|
(108)
-9%
|
(106)
+2%
|
(22)
+79%
|
(22)
+2%
|
(9)
+57%
|
(9)
+6%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
1
|
2
|
10
|
10
|
9
|
8
|
1
|
1
|
(0)
|
0
|
|
| Income from Continuing Operations |
(8)
|
(10)
|
(10)
|
(11)
|
(14)
|
(14)
|
(90)
|
(90)
|
(98)
|
(98)
|
(22)
|
(21)
|
(9)
|
(9)
|
|
| Net Income (Common) |
(8)
N/A
|
(10)
-20%
|
(10)
-2%
|
(21)
-116%
|
(24)
-13%
|
(24)
+1%
|
(108)
-351%
|
(98)
+10%
|
(106)
-9%
|
(106)
+1%
|
(22)
+79%
|
(21)
+2%
|
(9)
+56%
|
(9)
+6%
|
|
| EPS (Diluted) |
-307.38
N/A
|
-368.53
-20%
|
-377.67
-2%
|
-814.84
-116%
|
-917.81
-13%
|
-917
+0%
|
-2 118.18
-131%
|
-1 102.65
+48%
|
-1 089.7
+1%
|
-169.22
+84%
|
-26.18
+85%
|
-21.58
+18%
|
-8.48
+61%
|
-2.84
+67%
|
|
Switch to:
Switch to:
See Also
Discover More
